Oxurion NV Study
This study is currently closed to enrollment.
Oxurion NV / "A Phase 2, randomized, multicenter study to assess the dose level of multiple THR 149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME)"
Purpose of the Study
The purpose of this study is to find the best dose of THR-149 and to see how well THR-149 treats diabetic macular edema compared to an approved drug called aflibercept. Aflibercept (Eylea®) has been approved by the FDA to treat diabetic macular edema (DME).